Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Genetics
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-11
DOI
10.3389/fgene.2020.578011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A short guide to histone deacetylases including recent progress on class II enzymes
- (2020) Suk-Youl Park et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
- (2020) Sara Moufarrij et al. Scientific Reports
- Nicotinamide Overcomes Doxorubicin Resistance of Breast Cancer Cells through Deregulating SIRT1/Akt Pathway
- (2019) Yingze Wei et al. Anti-Cancer Agents in Medicinal Chemistry
- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
- (2019) Jonathan L. Kaufman et al. Blood Cancer Journal
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Metformin and tenovin‐6 synergistically induces apoptosis through LKB1‐independent SIRT1 down‐regulation in non‐small cell lung cancer cells
- (2019) Bo Bin Lee et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
- (2019) Debarati Banik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
- (2019) Fang-I Huang et al. Frontiers in Oncology
- HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
- (2019) Takeshi Fukumoto et al. CANCER RESEARCH
- Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
- (2019) Simone Moertl et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis
- (2019) Anna Wawruszak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
- (2018) Daniel O. Persky et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
- (2018) Sanjeeve Balasubramaniam et al. ANTI-CANCER DRUGS
- DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
- (2018) Angelique Bruyer et al. BRITISH JOURNAL OF CANCER
- Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
- (2018) G. R. Vanaja et al. Cell Communication and Signaling
- Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
- (2018) Marta Di Martile et al. Oncogenesis
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer
- (2018) Wenjing Ma et al. CANCER BIOLOGY & THERAPY
- The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma
- (2018) Daniel Jose García-Domínguez et al. Oncotarget
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
- (2018) Diana Llopiz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma
- (2018) Theodoros N. Teknos et al. INVESTIGATIONAL NEW DRUGS
- Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
- (2018) Khaldoun Rifaï et al. Cancers
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse
- (2017) Chana L. Glasser et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma
- (2017) Huilai Zhang et al. LEUKEMIA RESEARCH
- Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
- (2017) Parunya Chaiyawat et al. MODERN PATHOLOGY
- Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
- (2017) Blaz Groselj et al. MOLECULAR CANCER THERAPEUTICS
- Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B
- (2017) Haiyue Zhang et al. Molecular Medicine Reports
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
- (2017) Evanthia Galanis et al. NEURO-ONCOLOGY
- Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
- (2017) Tinka Haydn et al. Cell Death & Disease
- Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
- (2017) Theresa M Thole et al. Cell Death & Disease
- mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
- (2017) Clare F. Malone et al. Cancer Discovery
- Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
- (2017) Renier Heijkants et al. Oncotarget
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
- (2017) Aneta Grabarska et al. Journal of Cancer
- Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
- (2017) Brian J. North et al. PLoS One
- Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
- (2016) John A. Halsall et al. BIOESSAYS
- Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
- (2016) Elena Ceccacci et al. BRITISH JOURNAL OF CANCER
- Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth
- (2016) R. Pathania et al. CANCER RESEARCH
- Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
- (2016) Jennifer E. Amengual et al. CLINICAL CANCER RESEARCH
- Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study
- (2016) Jie Ji et al. EXPERIMENTAL HEMATOLOGY
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Erratum: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma
- (2016) S Sankar et al. ONCOGENE
- Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
- (2016) Emily Chan et al. RADIOTHERAPY AND ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
- (2015) Yuko Mishima et al. BRITISH JOURNAL OF HAEMATOLOGY
- Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
- (2015) John D. Hainsworth et al. CANCER
- Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
- (2015) Ken Saijo et al. CANCER SCIENCE
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
- (2015) T. J. Galloway et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
- (2015) S. G. DuBois et al. CLINICAL CANCER RESEARCH
- Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
- (2015) J. E. Amengual et al. CLINICAL CANCER RESEARCH
- Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines
- (2015) MD. ALI ASGAR et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
- (2015) Matthew Zibelman et al. INVESTIGATIONAL NEW DRUGS
- Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
- (2015) Valeria Santoro et al. JNCI-Journal of the National Cancer Institute
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
- (2015) Beata Holkova et al. LEUKEMIA & LYMPHOMA
- Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
- (2015) David E. Gerber et al. LUNG CANCER
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
- (2015) Katrin Liffers et al. Targeted Oncology
- Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
- (2015) Lisa Zhang et al. Oncotarget
- Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
- (2015) Valeria Santoro et al. JNCI-Journal of the National Cancer Institute
- Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
- (2014) S. Sankar et al. CLINICAL CANCER RESEARCH
- Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
- (2013) B Groselj et al. BRITISH JOURNAL OF CANCER
- The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma
- (2013) Jian Wu et al. DIGESTIVE DISEASES AND SCIENCES
- Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression
- (2013) Chenlin Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Histone Deacetylases
- (2013) Sabnam Parbin et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model
- (2013) Dingqing Feng et al. PLoS One
- Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication
- (2013) Qin Xu et al. Frontiers in Pharmacology
- Enhanced Angiogenic and Cardiomyocyte Differentiation Capacity of Epigenetically Reprogrammed Mouse and Human Endothelial Progenitor Cells Augments Their Efficacy for Ischemic Myocardial Repair
- (2012) Melissa A. Thal et al. CIRCULATION RESEARCH
- Cancer epigenomics: beyond genomics
- (2012) Juan Sandoval et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- HDAC11 is a novel drug target in carcinomas
- (2012) Hedwig E. Deubzer et al. INTERNATIONAL JOURNAL OF CANCER
- Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein
- (2012) Youngmi Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells
- (2012) C Mackintosh et al. ONCOGENE
- Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease
- (2012) Karen N. McFarland et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas
- (2011) B. S. Taylor et al. Cancer Discovery
- research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
- (2010) Daniel Antunes Moreno et al. BRITISH JOURNAL OF HAEMATOLOGY
- HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling
- (2010) Cassandra A. Godman et al. CANCER BIOLOGY & THERAPY
- Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
- (2010) Heiner Adams et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- (2009) P N Munster et al. BRITISH JOURNAL OF CANCER
- CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin
- (2009) Sara A Wickström et al. EMBO JOURNAL
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
- (2008) Sarah K Knutson et al. EMBO JOURNAL
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now